By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, ...

Patients with late-stage lung and skin cancer may have just won an unlikely ally: the COVID-19 mRNA vaccine. Researchers at the University of Florida and the University of Texas MD Anderson Cancer ...

Please provide your email address to receive an email when new articles are posted on . Researchers assessed Moderna’s RSV vaccine in solid organ transplant patients. The vaccine was safe and ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Messenger RNA technology, better known as mRNA technology, made it possible to rapidly deploy a new vaccine during the COVID-19 pandemic — much earlier than would otherwise have been possible, saving ...

A pharmacist holds a Pfizer and BioNTech COVID-19 vaccine shot on Thursday, April 24, 2025, in Portland, Ore. University of Florida researchers found that advanced lung and skin cancer patients lived ...